more good test results
COTI-2 in Combination With Taxol(R) (Paclitaxel) Is Superior to Treatment With Paclitaxel Alone in an Animal Model of Aggressive Human Endometrial Can
Thu May 14, 9:39 AM
LONDON, ONTARIO--(Marketwire - May 14, 2009) - Critical Outcome Technologies Inc. (TSX VENTURE: COT.V), announced positive results today from animal experiments carried out at a prominent American cancer research facility. The following results provide strong supportive evidence for the continued evaluation of COTI-2 in combination with conventional first line single agent therapy for the treatment of endometrial cancer:
- Up to 40% complete tumor regression (weight equals 0 mg) was observed in the combination treatment groups (paclitaxel plus COTI-2) while no complete regressions (0%) occurred in the paclitaxel alone treatment group.
- The combination treatment with paclitaxel plus COTI-2 was associated with a statistically significant improvement in absolute survival compared with the paclitaxel group.
- The tumor growth inhibition was 71.5% greater in the paclitaxel plus COTI-2 treated animals compared with paclitaxel alone.
- Combination treatments were well tolerated.
"We are delighted to see that intravenous COTI-2 in combination with paclitaxel showed superior treatment results compared to paclitaxel alone as measured by an improved tumor regression rate, an improved survival rate and delayed tumor growth in an animal model of aggressive human endometrial cancer (AN3-CA). These results are significant as they add to the impressive data set of COTI-2, showing efficacy against multiple cancers and low toxicity," said Dr. Wayne Danter, President and Chief Scientific Officer (CSO) of Critical Outcome Technologies Inc. (COTI).
COTI will present this new data to parties who have expressed interest in a commercial partnership related to COTI-2, including executives from several major pharmaceutical organizations, at BIO taking place May 18-21, 2009 in Atlanta, GA. "This new data will stimulate further discussions as we continue to evaluate our options pertaining to a licensing arrangement for COTI-2," said Mr. Michael Cloutier, Chief Executive Officer (CEO) of COTI. COTI will be represented at BIO by Mr. Michael Cloutier, CEO, Dr. Wayne Danter, President and CSO and Mr. Michael Barr, Director of Business Development and Marketing.